Clinical Trial Update: Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety and pharmacokinetics of the BGB-283 (lifirafenib) and PD-0325901 (mirdametinib) combination in adults with advanced or refractory…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• BGB-283 (lifirafenib) (lifirafenib)
• PD-0325901 (mirdametinib) (mirdametinib)

Snippet

Sponsor: BeiGene | Conditions: Solid Tumor, Adult | Phase 1 | Status: COMPLETED